HealthDay News — Complete vaccination with the 4-component, protein-based meningococcal serogroup B vaccine (4CMenB) is effective for preventing invasive meningococcal disease in children younger than 5 years, according to a study published in the February 2 issue of the New England Journal of Medicine.
Jesús Castilla, MD, PhD, from the Instituto de Salud Pública de Navarra in Pamplona, Spain, and colleagues examined the effectiveness of 4CMenB in preventing invasive meningococcal disease in children in a nationwide matched case-control study. All laboratory-confirmed cases of invasive meningococcal disease in children younger than 60 months between October 5, 2015, and October 6, 2019, were identified; 306 cases (79.4% with serogroup B disease) were matched to 1224 controls.
The researchers found that 11.4 and 24.3% of case patients and controls, respectively, had received at least one dose of 4CMenB. The effectiveness against invasive meningococcal disease caused by any serogroup was 76% for complete vaccination (receipt of at least 2 doses) and 54% for partial vaccination. The effectiveness against meningococcal serogroup B disease was 71% for complete vaccination. Vaccine effectiveness with at least one dose of 4CMenB was 64 and 82% against serogroup B disease and non-serogroup B disease, respectively. Forty-four case patients had serogroup B strains that were expected to be covered by 4CMenB; none of these patients had been vaccinated.
“This evidence may be useful in making decisions about the inclusion of this vaccine in the immunization program of countries where invasive meningococcal disease in children is problematic and its prevention a priority,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)